Stock Detail
SINOVAC BIOTECH LTD - ORDINARY SHARES (ANTIGUA/BARBUDO)
Sector: Biotechnology
Latest Quote @ Thu May 5 11:58:33 (15 min delayed)
| $3.37 |
$3.38 |
$3.37 |
+0.02 |
0.60% |
|
Last Day's Data
| $3.35 |
$3.48 |
$0.00 |
0.00% |
0.00 |
$3.40 |
| $3.43 |
$3.35 |
259,340.00 |
184.44M |
364,311.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 3.52 |
3.43 |
3.39 |
3.30 |
3.26 |
Stock Profile
Sinovac Biotech, Ltd. engages in the research, development, commercialization, and sale of human-use vaccines and related products for infectious diseases. It offers Healive, a vaccine for hepatitis A; Bilive, a combined vaccine for hepatitis A and B; and Anflu, a split flu vaccine. The company is also developing SARS vaccine, which is in phase I clinical trails, as well as has a co development agreement with the China Centre of Disease Control and Prevention for the development of Avian Flu-Pandemic Influenza Vaccine. Sinovac Biotech was founded in 1999 and is headquartered in Beijing, China.
